Initial Disclosure Notices

Initial Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(1) and 298(1), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
3 April 2024
Date on which issuer listed or appointment made:
1 April 2024
Director or senior manager giving disclosure
Full name:
Andrew Grant Niccol
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Operating Officer
Summary of relevant interest (excluding specified derivatives)
Class of quoted financial product:
(a) Ordinary Shares
(b) Options to acquire Ordinary Shares
(c) Performance Share Rights
Number held in class:
(a) 1501 Ordinary Shares, including a beneficial
interest in 131 shares issued to a trustee under an
Employee Share Purchase Scheme
(b) 25,066 Options
(c) 12,146 Performance Share Rights
Nature of relevant interest: Beneficial
Current registered holder: Andrew Grant Niccol
Summary of specified derivatives relevant interest (if applicable)
Type of derivative:
Class of underlying financial products:
Details of derivative
The notional value of the derivative (if any) or the notional amount of underlying
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price specified in the terms of the derivative(if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by the value
of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Certification
I, certify that, to the best of my knowledge and belief, the information contained in
this disclosure is correct and that I am duly authorised to make this disclosure by
all persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:3 April 2024
Name and title of authorised person:Raelene Leonard, Company Secretary

---

Initial Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(1) and 298(1), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
3 April 2024
Date on which issuer listed or appointment made:
1 April 2024
Director or senior manager giving disclosure
Full name:
Justin Peter Callahan
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Vice President - Sales & Marketing
Summary of relevant interest (excluding specified derivatives)
Class of quoted financial product:
(a) Ordinary Shares
(b) Options to acquire Ordinary Shares
(c) Performance Share Rights
Number held in class:
(a) 177,161 Ordinary Shares
(b) 98,992 Options
(c) 47,948 Performance Share Rights
Nature of relevant interest: Beneficial
Current registered holder: Justin Peter Callahan
Summary of specified derivatives relevant interest (if applicable)
Type of derivative:
Class of underlying financial products:
Details of derivative
The notional value of the derivative (if any) or the notional amount of underlying
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price specified in the terms of the derivative(if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:3 April 2024
Name and title of authorised person:Raelene Leonard, Company Secretary